Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report

To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. Cross-sectional and retrospective study of thirty cases treated over a period of two decades. 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one...

Full description

Saved in:
Bibliographic Details
Published in:Clinics (São Paulo, Brazil) Brazil), 2017-04, Vol.72 (4), p.218-223
Main Authors: de Fátima Borges, Maria, Lara, Beatriz Hallal Jorge, Tomé, Janaíne Machado, de Araújo, Leopoldo Prezia, Bugiga, Flávio Cesar Lucas, Sousa, Júlio Cláudio, Soares, Jacqueline Mendes Fonseca, Dezena, Roberto Alexandre, Ferreira, Beatriz Pires
Format: Article
Language:English
Subjects:
Acromegaly
Acromegaly - blood
Acromegaly - therapy
Adenoma - metabolism
Adenoma - surgery
Adolescent
Adult
Aged
Aged, 80 and over
Blood Glucose - analysis
Brazil
Clinical Science
Combined Modality Therapy
Cross-Sectional Studies
Female
Gigantism
Gigantism - blood
Gigantism - therapy
Growth Hormone - blood
Growth Hormone-Secreting Pituitary Adenoma - surgery
Humans
Insulin-Like Growth Factor I - analysis
Ligands
Male
MEDICINE, GENERAL & INTERNAL
Middle Aged
Outcome
Receptors, Somatostatin - metabolism
Retrospective Studies
Treatment
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. Cross-sectional and retrospective study of thirty cases treated over a period of two decades. 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphenoidal surgery, whichwas associated with somatostatin receptor ligands in 11 patients (39.3%), somatostatin receptor ligands + radiotherapyin 5 patients (17.8%), radiotherapy in 3 patients (10.7%), and radiotherapy + somatostatin receptorligands + cabergoline in 1 patient (3.6%). Additionally, 2 patients underwent radiotherapy and surgeryalone. Six patients received somatostatin receptor ligands before surgery, and 2 were not treated due to refusal and death. Nine patients have died, and 20 are being followed; 13 (65%) have growth hormonelevels o1 ng/mL, and 11 have normal insulin-like growth factor 1 levels. The current treatment options enable patients seen in regional reference centers to achieve strict control parameters, which allows them to be treated close to their homes.
ISSN:1807-5932
1980-5322
1980-5322
DOI:10.6061/clinics/2017(04)05